Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).
It is important that physicians raise awareness around the condition of generalized pustular psoriasis (GPP) in order to close the current diagnostic gap, says Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1.
Transcript
How is AI being used to identify patients with GPP?
GPP—generalized pustular psoriasis—is a rare, very serious dermatologic condition. I've seen literature that says more than half of patients with GPP are misdiagnosed into another condition before they receive the correct diagnosis of GPP. And until recently, there hasn't really been good treatment options for them; now there is.
The thing that we've tackled in our work, between OM1 and collaboration with AAD [American Academy of Dermatology] and sponsored by BI [Boehringer Ingelheim] has been to use artificial intelligence to say, of patients that we know with GPP, what do those patients share in their real-world data? So, in their diagnoses, medications they've taken, providers they've seen; all those data points. What do they share prior to their GPP diagnosis that's common to those patients, but that distinguishes them from everybody else?
AI is very good at understanding and recognizing those kinds of patterns and those similarities among patients. And once that's done, if everything works well, an AI system like our PhenOM system is able to use that sort of digital fingerprint to then look at new patients; to look at others in large datasets, in an electronic health record or health system and say, "Are there other patients whose data records match this known phenotypic fingerprint, but who don't have this GPP diagnosis?" Because if that's the case, we can highlight that person to say this is someone who probably warrants a second look by a specialist to see if they have this condition. I can report happily that we've completed the work of figuring out if this is analytically possible. It is; it works quite well. I'm excited to see what this work will do [in] raising awareness around this condition in the dermatology community as well as in practice, helping to highlight these patients and close that diagnostic gap.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Scalp Repair Serum Microneedling: Fewer Treatments, More Hair Regrowth for AGA
May 14th 2024A study found scalp repair serum microneedle combined therapy with medication to improve hair growth outcomes for patients with moderate to severe androgenetic alopecia (AGA) and reduce the number of microneedling sessions necessary.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More